Certara offers predictive science and informatics solutions that enable cross-disciplinary and translational approaches to drug development.
The IVIVC Toolkit for Phoenix WinNonlin expands the capabilities of Phoenix WinNonlin, enabling the use of Phoenix WinNonlin for in vivo-in vitro correlations (IVIVC). The Toolkit brings enhanced deconvolution methods, numerical convolution, new plotting capability, and the “IVIVC Wizard” to pharmacokineticists and formulators. Now you can use Phoenix WinNonlin to speed formulation development, improve chances of success in bioequivalence studies, and much more.
IVIVC Toolkit can save you money. IVIVC can allow you to substitute fast, relatively inexpensive dissolution analysis for slow, expensive bioavailability or bioequivalence (BA/BE) studies. The Product Quality Research Institute says the average NDA has 3-6 BA/BE studies. The savings from avoided BA/BE testing can create a powerful ROI for your investment in IVIVC Toolkit.
IVIVC Toolkit can save you time. Pharsight estimates that a typical BA/BE study requires a total of 3 months, end to end, to write the protocol, recruit patients, conduct bioanalytic work, and analyze the results. Saving even 1 or 2 BA/BE studies can knock months off time-to-market.
Using Excel for IVIVC? Most users of IVIVC Toolkit find they benefit from many features that Excel simply doesn't have: dialogue-guided wizards and tools to streamline the workflow, automatic estimation of UIR, and workflow support for a complete, 2-stage IVIVC to name just a few.
Run multiple inputs over multiple responses at once
Assess time-scale of dissolution experiments
IVIVC Toolkit for Phoenix WinNonlin is supported for both 32-bit and 64-bit versions of Windows XP SP3, Windows 2003, Windows 7 SP1, Windows 2008 Server R2.
Minimum Hardware Requirements:
Processor: Intel Core 2 Duo 2.0 Ghz, or a CPU of EQUIVALENT processing power
RAM: 2 gigabytes RAM
Hard drive space: 300 megabytes free
Click here for detailed system requirements, including international language support.